Matthew G. Parry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Matthew G. Parry has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
Heather Payne
Department of Oncology University College London Hospitals London UK
20 shared publicationsNoel W. Clarke
Department of Urology The Christie and Salford Royal Hospitals Manchester UK
20 shared publicationsAjay Aggarwal
Department of Health Services Research & Policy London School of Hygiene & Tropical Medicine London UK
19 shared publicationsJan van der Meulen
National Cancer Audit Collaborating Centre, Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK; Department of Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, UK
17 shared publicationsPaul Cathcart
Department of Urology, Guy's & St Thomas' NHS Foundation Trust, UK
16 shared publicationsArunan Sujenthiran
The National Prostate Cancer Audit, Clinical Effectiveness Unit Royal College of Surgeons of England London UK
15 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Wiley in BJU International
- Vol. 138 (6) , 1007-1010
Improved survival in newly diagnosed metastatic prostate cancer: a National Prostate Cancer Audit study
- 8 October 2026
- Published by Wiley in BJU International
- Vol. 138 (6) , 1007-1010
Open AccessImproved survival in newly diagnosed metastatic prostate cancer: a National Prostate Cancer Audit study
- Open Access
- 18 April 2026
- Published by Springer Nature in BMC Urology
- Vol. 26 (1)
Impact of comorbidity on patient reported outcome measures for men with localised prostate cancer
Background: Urinary and sexual function are impacted by prostate cancer treatment but also by comorbidities. We aimed to report the impact of comorbidities on functional outcomes after prostate cancer treatment. Methods: We used patient reported EPIC-26, at baseline and 12 months, from a multicenter, prospective international cohort. Forest plots were constructed for urinary and sexual function, according to treatment, age and comorbidities (heart disease, hypertension and diabetes mellitus). Results: We identified 10,928 patients diagnosed with non-metastatic prostate cancer with complete PROMs at baseline and at 12 months. Urinary and sexual function at baseline varied with age and comorbidities, but the biggest impact on 12-month function was the treatment itself. Surgery had a greater impact on urinary function compared to radiotherapy, irrespective of comorbidities, but this was only observed for sexual function in those with no comorbidities. Men of younger age and those with no comorbidities had the best preservation of urinary and sexual function after treatment, but a floor effect was observed whereby those with better baseline sexual function reported larger post-treatment differences. Conclusions: The impact of age and comorbidity on functional outcomes after prostate cancer treatment is minimal when considered against the impact of the treatment itself.
- 18 April 2026
- Published by Springer Nature in BMC Urology
- Vol. 26 (1)
Open AccessImpact of comorbidity on patient reported outcome measures for men with localised prostate cancer
Background: Urinary and sexual function are impacted by prostate cancer treatment but also by comorbidities. We aimed to report the impact of comorbidities on functional outcomes after prostate cancer treatment. Methods: We used patient reported EPIC-26, at baseline and 12 months, from a multicenter, prospective international cohort. Forest plots were constructed for urinary and sexual function, according to treatment, age and comorbidities (heart disease, hypertension and diabetes mellitus). Results: We identified 10,928 patients diagnosed with non-metastatic prostate cancer with complete PROMs at baseline and at 12 months. Urinary and sexual function at baseline varied with age and comorbidities, but the biggest impact on 12-month function was the treatment itself. Surgery had a greater impact on urinary function compared to radiotherapy, irrespective of comorbidities, but this was only observed for sexual function in those with no comorbidities. Men of younger age and those with no comorbidities had the best preservation of urinary and sexual function after treatment, but a floor effect was observed whereby those with better baseline sexual function reported larger post-treatment differences. Conclusions: The impact of age and comorbidity on functional outcomes after prostate cancer treatment is minimal when considered against the impact of the treatment itself.
- Open Access
- 17 February 2026
- Published by Wiley in BJU International
- Vol. 137 (5) , 840-848
Characteristics and outcomes of men presenting with complications of metastatic prostate cancer
Objectives: To describe the incidence, characteristics and mortality of men who present with complications of metastatic prostate cancer, a previously under‐reported population. We investigate men who present with and without malignant ureteric obstruction (MUO) and skeletal‐related events (SREs), collectively termed ‘metastatic‐related events’ (MREs). Patients and Methods: We used the English Cancer Registry linked to hospital administrative data to identify men diagnosed with metastatic prostate cancer between January 2015 and December 2022. Poisson regression models estimated adjusted relative risks (aRRs) of presenting with MREs. The cumulative incidences of overall and prostate cancer‐specific death were estimated for each MRE subgroup (metastatic without MRE, MUO, SRE, and MUO and SRE in combination). Results: Of 48 171 men diagnosed with primary metastatic disease, 4272 (8.9%) presented with MREs. Of these men, 2453 (57.4%) had MUO, 1738 (40.7%) had a SRE, and 81 (1.9%) had both. Men aged ≥80 years had the highest risk (9.8% [1604/16452]) of presenting with MREs. Men aged 70–79 years (8.0% [1470/18397]) (aRR 0.82, 95% confidence interval [CI] 0.77–0.88) and men aged 60–69 years (8.9% [916/10297]) (aRR 0.91, 95%CI 0.84–0.98) had lower risks. Men from the most deprived neighbourhoods (9.3% [706/7609]) (aRR 1.27, 95% CI 1.15–1.40) had greater risks of presenting with MREs than those from the least deprived neighbourhoods (8.0% [868/10865]). The proportion of men presenting with MREs varied across geographical regions, ranging from 4.6% (288/6233) to 11.7% (461/3951). The 5‐year overall mortality for men presenting without MREs was 57.8% (95% CI 57.2–58.4%), compared to 77.1% (95% CI 74.9–79.2%) with MUO, 66.8% (95% CI 64.1–69.4%) with a SRE and 84.4% (95% CI 74.1–94.7%) with both. Conclusions: The risk of presenting with metastatic prostate cancer and MREs varies according to age, socioeconomic deprivation, and residential region. These men have poorer survival outcomes than men diagnosed without MREs at diagnosis.
- 17 February 2026
- Published by Wiley in BJU International
- Vol. 137 (5) , 840-848
Open AccessCharacteristics and outcomes of men presenting with complications of metastatic prostate cancer
Objectives: To describe the incidence, characteristics and mortality of men who present with complications of metastatic prostate cancer, a previously under‐reported population. We investigate men who present with and without malignant ureteric obstruction (MUO) and skeletal‐related events (SREs), collectively termed ‘metastatic‐related events’ (MREs). Patients and Methods: We used the English Cancer Registry linked to hospital administrative data to identify men diagnosed with metastatic prostate cancer between January 2015 and December 2022. Poisson regression models estimated adjusted relative risks (aRRs) of presenting with MREs. The cumulative incidences of overall and prostate cancer‐specific death were estimated for each MRE subgroup (metastatic without MRE, MUO, SRE, and MUO and SRE in combination). Results: Of 48 171 men diagnosed with primary metastatic disease, 4272 (8.9%) presented with MREs. Of these men, 2453 (57.4%) had MUO, 1738 (40.7%) had a SRE, and 81 (1.9%) had both. Men aged ≥80 years had the highest risk (9.8% [1604/16452]) of presenting with MREs. Men aged 70–79 years (8.0% [1470/18397]) (aRR 0.82, 95% confidence interval [CI] 0.77–0.88) and men aged 60–69 years (8.9% [916/10297]) (aRR 0.91, 95%CI 0.84–0.98) had lower risks. Men from the most deprived neighbourhoods (9.3% [706/7609]) (aRR 1.27, 95% CI 1.15–1.40) had greater risks of presenting with MREs than those from the least deprived neighbourhoods (8.0% [868/10865]). The proportion of men presenting with MREs varied across geographical regions, ranging from 4.6% (288/6233) to 11.7% (461/3951). The 5‐year overall mortality for men presenting without MREs was 57.8% (95% CI 57.2–58.4%), compared to 77.1% (95% CI 74.9–79.2%) with MUO, 66.8% (95% CI 64.1–69.4%) with a SRE and 84.4% (95% CI 74.1–94.7%) with both. Conclusions: The risk of presenting with metastatic prostate cancer and MREs varies according to age, socioeconomic deprivation, and residential region. These men have poorer survival outcomes than men diagnosed without MREs at diagnosis.
- 22 March 2024
- Published by Wiley in BJU International
- Vol. 134 (2) , 313
Reply to: Letter to the editor regarding the article ‘Prostate cancer outcomes following whole‐gland and focal high‐intensity focused ultrasound’
- 22 March 2024
- Published by Wiley in BJU International
- Vol. 134 (2) , 313
Reply to: Letter to the editor regarding the article ‘Prostate cancer outcomes following whole‐gland and focal high‐intensity focused ultrasound’
- Open Access
- 25 July 2023
- Published by Wiley in BJU International
- Vol. 132 (5) , 568-574
Prostate cancer outcomes following whole‐gland and focal high‐intensity focused ultrasound
Objective: To report the 5‐year failure‐free survival (FFS) following high‐intensity focused ultrasound (HIFU). Patients and Methods: This observational cohort study used linked National Cancer Registry data, radiotherapy data, administrative hospital data and mortality records of 1381 men treated with HIFU for clinically localised prostate cancer in England. The primary outcome, FFS, was defined as freedom from local salvage treatment and cancer‐specific mortality. Secondary outcomes were freedom from repeat HIFU, prostate cancer‐specific survival (CSS) and overall survival (OS). Cox regression was used to determine whether baseline characteristics, including age, treatment year, T stage and International Society of Urological Pathology (ISUP) Grade Group were associated with FFS. Results: The median (interquartile range [IQR]) follow‐up was 37 (20–62) months. The median (IQR) age was 65 (59–70) years and 81% had an ISUP Grade Group of 1–2. The FFS was 96.5% (95% confidence interval [CI] 95.4%–97.4%) at 1 year, 86.0% (95% CI 83.7%–87.9%) at 3 years and 77.5% (95% CI 74.4%–80.3%) at 5 years. The 5‐year FFS for ISUP Grade Groups 1–5 was 82.9%, 76.6%, 72.2%, 52.3% and 30.8%, respectively ( P < 0.001). Freedom from repeat HIFU was 79.1% (95% CI 75.7%–82.1%), CSS was 98.8% (95% CI 97.7%–99.4%) and OS was 95.9% (95% CI 94.2%–97.1%) at 5 years. Conclusion: Four in five men were free from local salvage treatment at 5 years but treatment failure varied significantly according to ISUP Grade Group. Patients should be appropriately informed with respect to salvage radical treatment following HIFU.
- 25 July 2023
- Published by Wiley in BJU International
- Vol. 132 (5) , 568-574
Open AccessProstate cancer outcomes following whole‐gland and focal high‐intensity focused ultrasound
Objective: To report the 5‐year failure‐free survival (FFS) following high‐intensity focused ultrasound (HIFU). Patients and Methods: This observational cohort study used linked National Cancer Registry data, radiotherapy data, administrative hospital data and mortality records of 1381 men treated with HIFU for clinically localised prostate cancer in England. The primary outcome, FFS, was defined as freedom from local salvage treatment and cancer‐specific mortality. Secondary outcomes were freedom from repeat HIFU, prostate cancer‐specific survival (CSS) and overall survival (OS). Cox regression was used to determine whether baseline characteristics, including age, treatment year, T stage and International Society of Urological Pathology (ISUP) Grade Group were associated with FFS. Results: The median (interquartile range [IQR]) follow‐up was 37 (20–62) months. The median (IQR) age was 65 (59–70) years and 81% had an ISUP Grade Group of 1–2. The FFS was 96.5% (95% confidence interval [CI] 95.4%–97.4%) at 1 year, 86.0% (95% CI 83.7%–87.9%) at 3 years and 77.5% (95% CI 74.4%–80.3%) at 5 years. The 5‐year FFS for ISUP Grade Groups 1–5 was 82.9%, 76.6%, 72.2%, 52.3% and 30.8%, respectively ( P < 0.001). Freedom from repeat HIFU was 79.1% (95% CI 75.7%–82.1%), CSS was 98.8% (95% CI 97.7%–99.4%) and OS was 95.9% (95% CI 94.2%–97.1%) at 5 years. Conclusion: Four in five men were free from local salvage treatment at 5 years but treatment failure varied significantly according to ISUP Grade Group. Patients should be appropriately informed with respect to salvage radical treatment following HIFU.
- Open Access
- 11 April 2023
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 40, 100622
Treatment-related toxicity using prostate bed versus prostate bed and pelvic lymph node radiation therapy following radical prostatectomy: A national population-based study
- 11 April 2023
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 40, 100622
Open AccessTreatment-related toxicity using prostate bed versus prostate bed and pelvic lymph node radiation therapy following radical prostatectomy: A national population-based study
- Open Access
- 26 December 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 181, 70-78
A low prostate specific antigen predicts a worse outcome in high but not in low/intermediate-grade prostate cancer
- 26 December 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 181, 70-78
Open AccessA low prostate specific antigen predicts a worse outcome in high but not in low/intermediate-grade prostate cancer
- 12 May 2022
- Published by Wiley in BJU International
- Vol. 130 (5) , 688-695
Interventions for obstructive uropathy in advanced prostate cancer: a population‐based study
Objectives: To develop and validate a coding framework to identify interventions for upper tract obstructive uropathy (UTOU) in men with locally advanced and metastatic prostate cancer (PCa) using administrative hospital data to assess clinical outcomes. There are no population‐based studies on the incidence, treatment, and outcomes of this complication. Patients and Methods: Patients newly diagnosed with PCa between April 2014 and March 2019 were identified in the English cancer registry. A coding framework based on procedure (Office of Population Censuses and Surveys Classification of Surgical Operations and Procedures fourth edition) and diagnostic (International Classification of Diseases, 10th edition) codes was developed and validated. Subsequent clinical outcomes were determined using Hospital Episodes Statistics to determine the utility of the intervention. Results: A total of 77 010 patients newly diagnosed with locally advanced, and 30 083 patients with metastatic PCa were identified. Of these, 1951 (1.8%) patients underwent an intervention for UTOU according to our coding framework: 830 (42.5%) had locally advanced disease and 1121 (57.5%) had metastatic disease. In all, 844 (43.3%) had a percutaneous nephrostomy (PCN), 473 (24.2%) had a PCN with antegrade stent, and 634 (32.5%) had a retrograde stent. The mean follow‐up was 43.2 months. The cumulative incidence of the use of these interventions at 1, 3, and 5 years was 2.5%, 3.6% and 4.2% in men with metastases compared to 0.5%, 0.9% and 1.4% in men with locally advanced disease. Conclusion: A new coding framework, developed to identify procedures for UTOU was applied in the largest study to date of UTOU in men with primary locally advanced and metastatic PCa. Results demonstrated that 2% of men with locally advanced PCa and 4% of men with metastatic PCa require an intervention to resolve UTOU within 5 years of their PCa diagnosis.
- 12 May 2022
- Published by Wiley in BJU International
- Vol. 130 (5) , 688-695
Interventions for obstructive uropathy in advanced prostate cancer: a population‐based study
Objectives: To develop and validate a coding framework to identify interventions for upper tract obstructive uropathy (UTOU) in men with locally advanced and metastatic prostate cancer (PCa) using administrative hospital data to assess clinical outcomes. There are no population‐based studies on the incidence, treatment, and outcomes of this complication. Patients and Methods: Patients newly diagnosed with PCa between April 2014 and March 2019 were identified in the English cancer registry. A coding framework based on procedure (Office of Population Censuses and Surveys Classification of Surgical Operations and Procedures fourth edition) and diagnostic (International Classification of Diseases, 10th edition) codes was developed and validated. Subsequent clinical outcomes were determined using Hospital Episodes Statistics to determine the utility of the intervention. Results: A total of 77 010 patients newly diagnosed with locally advanced, and 30 083 patients with metastatic PCa were identified. Of these, 1951 (1.8%) patients underwent an intervention for UTOU according to our coding framework: 830 (42.5%) had locally advanced disease and 1121 (57.5%) had metastatic disease. In all, 844 (43.3%) had a percutaneous nephrostomy (PCN), 473 (24.2%) had a PCN with antegrade stent, and 634 (32.5%) had a retrograde stent. The mean follow‐up was 43.2 months. The cumulative incidence of the use of these interventions at 1, 3, and 5 years was 2.5%, 3.6% and 4.2% in men with metastases compared to 0.5%, 0.9% and 1.4% in men with locally advanced disease. Conclusion: A new coding framework, developed to identify procedures for UTOU was applied in the largest study to date of UTOU in men with primary locally advanced and metastatic PCa. Results demonstrated that 2% of men with locally advanced PCa and 4% of men with metastatic PCa require an intervention to resolve UTOU within 5 years of their PCa diagnosis.
- 8 March 2022
- Published by Springer Nature in Nature Reviews Urology
- Vol. 19 (5) , 263-279
Implementation of patient-reported outcome measures into health care for men with localized prostate cancer
Measuring treatment-related quality of life (QOL) has become an increasingly requisite component of delivering high-quality care for patients with prostate cancer. Patient-reported outcome measures (PROMs) have, therefore, become an important tool for understanding the adverse effects of radical prostate cancer treatment and have been widely integrated into clinical practice. By providing real-time symptom monitoring and improved clinical feedback to patients and providers, PRO assessment has led to meaningful gains in prostate cancer care delivery and quality improvement worldwide. By providing an avenue for benchmarking, collaboration and population health monitoring, PROMs have delivered substantial improvements beyond providing individual symptom feedback. However, multilevel barriers exist that need to be addressed before the routine implementation of PROMs is achieved. Improvements in collection, interpretation, standardization and reporting will be crucial for the continued implementation of PROM instruments in prostate cancer pathways.
- 8 March 2022
- Published by Springer Nature in Nature Reviews Urology
- Vol. 19 (5) , 263-279
Implementation of patient-reported outcome measures into health care for men with localized prostate cancer
Measuring treatment-related quality of life (QOL) has become an increasingly requisite component of delivering high-quality care for patients with prostate cancer. Patient-reported outcome measures (PROMs) have, therefore, become an important tool for understanding the adverse effects of radical prostate cancer treatment and have been widely integrated into clinical practice. By providing real-time symptom monitoring and improved clinical feedback to patients and providers, PRO assessment has led to meaningful gains in prostate cancer care delivery and quality improvement worldwide. By providing an avenue for benchmarking, collaboration and population health monitoring, PROMs have delivered substantial improvements beyond providing individual symptom feedback. However, multilevel barriers exist that need to be addressed before the routine implementation of PROMs is achieved. Improvements in collection, interpretation, standardization and reporting will be crucial for the continued implementation of PROM instruments in prostate cancer pathways.